Influence of Magnetic Field Strength on Magnetic Resonance Imaging Radiomics Features in Brain Imaging, an

heterogeneous phantom homogeneous phantom magnetic fields magnetic resonance imaging texture tissue features

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 10 03 2020
accepted: 23 11 2020
entrez: 8 2 2021
pubmed: 9 2 2021
medline: 9 2 2021
Statut: epublish

Résumé

The development and clinical adoption of quantitative imaging biomarkers (radiomics) has established the need for the identification of parameters altering radiomics reproducibility. The aim of this study was to assess the impact of magnetic field strength on magnetic resonance imaging (MRI) radiomics features in neuroradiology clinical practice. T1 3D SPGR sequence was acquired on two phantoms and 10 healthy volunteers with two clinical MR devices from the same manufacturer using two different magnetic fields (1.5 and 3T). Phantoms varied in terms of gadolinium concentrations and textural heterogeneity. 27 regions of interest were segmented (phantom: 21, volunteers: 6) using the LIFEX software. 34 features were analyzed. In the phantom dataset, 10 (67%) out of 15 radiomics features were significantly different when measured at 1.5T or 3T (student's t-test, p < 0.05). Gray levels resampling, and pixel size also influence part of texture features. These findings were validated in healthy volunteers. According to daily used protocols for clinical examinations, radiomic features extracted on 1.5T should not be used interchangeably with 3T when evaluating texture features. Such confounding factor should be adjusted when adapting the results of a study to a different platform, or when designing a multicentric trial.

Sections du résumé

BACKGROUND BACKGROUND
The development and clinical adoption of quantitative imaging biomarkers (radiomics) has established the need for the identification of parameters altering radiomics reproducibility. The aim of this study was to assess the impact of magnetic field strength on magnetic resonance imaging (MRI) radiomics features in neuroradiology clinical practice.
METHODS METHODS
T1 3D SPGR sequence was acquired on two phantoms and 10 healthy volunteers with two clinical MR devices from the same manufacturer using two different magnetic fields (1.5 and 3T). Phantoms varied in terms of gadolinium concentrations and textural heterogeneity. 27 regions of interest were segmented (phantom: 21, volunteers: 6) using the LIFEX software. 34 features were analyzed.
RESULTS RESULTS
In the phantom dataset, 10 (67%) out of 15 radiomics features were significantly different when measured at 1.5T or 3T (student's t-test, p < 0.05). Gray levels resampling, and pixel size also influence part of texture features. These findings were validated in healthy volunteers.
CONCLUSIONS CONCLUSIONS
According to daily used protocols for clinical examinations, radiomic features extracted on 1.5T should not be used interchangeably with 3T when evaluating texture features. Such confounding factor should be adjusted when adapting the results of a study to a different platform, or when designing a multicentric trial.

Identifiants

pubmed: 33552944
doi: 10.3389/fonc.2020.541663
pmc: PMC7855708
doi:

Types de publication

Journal Article

Langues

eng

Pagination

541663

Informations de copyright

Copyright © 2021 Ammari, Pitre-Champagnat, Dercle, Chouzenoux, Moalla, Reuze, Talbot, Mokoyoko, Hadchiti, Diffetocq, Volk, El Haik, Lakiss, Balleyguier, Lassau and Bidault.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Appl Clin Med Phys. 2020 Jan;21(1):179-190
pubmed: 31880401
J Magn Reson Imaging. 2018 May;47(5):1380-1387
pubmed: 28926163
Magn Reson Imaging. 2004 Jan;22(1):81-91
pubmed: 14972397
Magn Reson Imaging. 1999 Sep;17(7):1025-31
pubmed: 10463653
Med Phys. 2009 Apr;36(4):1236-43
pubmed: 19472631
Phys Med Biol. 2016 Jul 7;61(13):R150-66
pubmed: 27269645
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1544-1545
pubmed: 27479727
Sci Rep. 2017 Oct 16;7(1):13206
pubmed: 29038455
Sci Rep. 2015 Jun 05;5:11044
pubmed: 26251068
Cancer Radiother. 2017 Oct;21(6-7):648-654
pubmed: 28865968
Med Phys. 2017 Mar;44(3):1050-1062
pubmed: 28112418
Transl Oncol. 2016 Apr;9(2):155-162
pubmed: 27084432
Phys Med. 2020 Mar;71:71-81
pubmed: 32092688
Sci Rep. 2017 Aug 11;7(1):7952
pubmed: 28801575
J Nucl Med. 2014 Mar;55(3):414-22
pubmed: 24549286
Eur Radiol. 2019 Mar;29(3):1616-1624
pubmed: 30105410
Sci Rep. 2020 Jul 23;10(1):12340
pubmed: 32704007
Med Phys. 2019 Nov;46(11):5116-5123
pubmed: 31539450
Sci Rep. 2017 Sep 4;7(1):10353
pubmed: 28871110
Clin Cancer Res. 2018 Dec 15;24(24):6288-6299
pubmed: 30054278
Magn Reson Imaging. 1993;11(6):817-33
pubmed: 8371637
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2638-2655
pubmed: 31240330
Eur Radiol. 2017 Nov;27(11):4498-4509
pubmed: 28567548
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
Med Phys. 2011 Sep;38(9):5058-66
pubmed: 21978050
J Nucl Med. 2015 Nov;56(11):1642-4
pubmed: 26294296
Ann Oncol. 2017 Jun 1;28(6):1191-1206
pubmed: 28168275
J Nucl Med. 2017 Mar;58(3):387-392
pubmed: 27754906
Magn Reson Med. 1994 Jul;32(1):121-8
pubmed: 8084227
J Med Imaging (Bellingham). 2019 Apr;6(2):024502
pubmed: 31259199
Sci Rep. 2018 Mar 23;8(1):5087
pubmed: 29572492
Med Phys. 2004 Mar;31(3):616-22
pubmed: 15070262
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Chin Clin Oncol. 2017 Aug;6(4):40
pubmed: 28841802

Auteurs

Samy Ammari (S)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Stephanie Pitre-Champagnat (S)

BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Laurent Dercle (L)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
Immunology of Tumours and Immunotherapy INSERM U1015, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.
Radiology Department, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, United States.

Emilie Chouzenoux (E)

Center for Visual Computing, CentraleSupelec, Inria, Université Paris-Saclay, Gif-sur-Yvette, France.

Salma Moalla (S)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Sylvain Reuze (S)

Department of Radiotherapy - Medical Physics, Gustave Roussy, Université ParisSaclay, Villejuif, France.

Hugues Talbot (H)

Center for Visual Computing, CentraleSupelec, Inria, Université Paris-Saclay, Gif-sur-Yvette, France.

Tite Mokoyoko (T)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Joya Hadchiti (J)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Sebastien Diffetocq (S)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Andreas Volk (A)

BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Mickeal El Haik (M)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Sara Lakiss (S)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

Corinne Balleyguier (C)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Nathalie Lassau (N)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Francois Bidault (F)

Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Classifications MeSH